Dr. Jimmy Caudell Jr., MD

Dr. Caudell practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Caudell's NPI, 1376753889, was assigned on May 23, 2007. Dr. Caudell graduated from McGovern Medical School in 2004. Dr. Caudell's Mississippi license number on file is 20557.

Dr. Caudell's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Caudell's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Caudell to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Caudell practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Caudell's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Caudell is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Caudell's licenses on file in 3 states: Mississippi, Florida and Alabama.

Dmand AI lists bone cancer radiation, brain cancer radiation and head & neck cancer radiation among the conditions Dr. Caudell treats.

CMS data shows 1,621 Medicare services from Dr. Caudell across 15 procedure codes in 2024, for 414 Medicare patients. Medicare paid $95,232 for them.

CMS counts 414 Medicare patients who saw Dr. Caudell in 2024. The largest group is 65 to 74, with 217 patients. 75% of them have high cholesterol, and 74% have high blood pressure. 5% are also on Medicaid. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Caudell's median patient age at 68, with 42% women.

In 2024, Dr. Caudell wrote 115 Medicare Part D claims for 44 patients. 92% of them were for generic drugs. CMS names the drug for 52 of them, across 3 drugs with 11 or more claims each, at $622 in total drug cost. In 2023, CMS named 29 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Caudell for performance year 2024, reported as part of a group. Dr. Caudell accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 109 papers to Dr. Caudell, published from 2008 to 2025. 2016 was the busiest year, with 7. The most frequent topics are Head and Neck Neoplasms, Carcinoma, Squamous Cell and Radiotherapy Dosage. Dr. Caudell has published most often in Int J Radiat Oncol Biol Phys. Dr. Caudell's most frequent co-authors are Louis B. Harrison, MD, Arash Olyie Naghavi, MD and Javier F. Torres-Roca, MD.

Dmand AI links Dr. Caudell to 2 clinical trials. Conditions studied include Laryngeal Diseases, Neoplasms, Squamous Cell and Oropharyngeal Neoplasms. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 2.

CMS Open Payments shows 37 general payments to Dr. Caudell from 10 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 80% of the total. Varian Medical Systems, Inc. paid the most, $13,833.

Dr. Caudell graduated from McGovern Medical School in 2004.

Dr. Caudell is in network with 8 carriers, including Excellus BlueCross BlueShield, United Healthcare and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.